Deficiency consequences of lipid malabsorption disorders : are we able to prevent them?
Events
The 10/04/2012 at 09:36:56
Orphan Europe will organise a satellite symposium during the ESPGHAN Update 2012 meeting in Stockholm on Saturday 28th April
“Deficiency consequences of lipid malabsorption disorders : Are we able to prevent them”.
Please come and visit our booth in the exhibition space
Rare Disease Day 2012
News
The 27/01/2012 at 16:34:02
Rare Disease Day is an annual, awareness-raising event co-ordinated by EURORDIS at the international level and the National Alliances of Patient Organisations at the national level.
Orphan Europe is pleased to announce that Normosang (human hemin) has received market approval, in Russia for the treatment of acute attacks of hepatic porphyria (acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. Download here
RECORDATI: APPROVAL GRANTED FOR THE USE OF CARBAGLU® IN THE TREATMENT OF ORGANIC ACIDAEMIAS
The 01/06/2011 at 11:12:52
Orphan Europe has received approval from the European Commission to extend the use of Carbaglu® (carglumic acid) to treat hyperammonaemia due to one of the three main organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia). Carbaglu® has orphan drug designation and since 2003 is indicated in the treatment of NAGS deficiency.
ORPHAN EUROPE (RECORDATI GROUP) RECEIVES 2011 CORPORATE AWARD FROM THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) FOR THE DEVELOPMENT OF CARBAGLUR FOR THE TREATMENT OF NAGS DEFICIENCY
The 01/06/2011 at 10:53:13
Paris, France . May 18, 2011.
Orphan Europe has received the 2011 Corporate Award from the National Organization for Rare Disorders (NORD). Orphan Europe was recognized for making Carbaglu (carglumic acid) tablets available in the U.S. for the treatment of a condition known as NAGS deficiency.
Orphan Europe, part of the Recordati group, announces that the U.S. Food and Drug Administration (FDA) approved Carbaglu® (carglumic acid) for use in paediatric and adult patients for the treatment of acute hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylgutamate synthase (NAGS deficiency) and as maintenance therapy for chronic hyperammonaemia due to NAGS deficiency.
December 13th 2007 - Recordati S.p.A. announced the successful conclusion of its acquisition of Orphan Europe announced on 28 September last, following clearance from the relevant anti-trust authorities. The purchase price is € 135 million.
8th Middle East Metabolic Group meeting October 27th - 29th 2011, Lebanon
Events
The 20/10/2011 at 16:10:44
Dear Colleagues, On behalf of the department of pediatrics Hotel Dieu de France Hospital, it is my pleasure to invite you to Lebanon to participate in the 8th Middle East Metabolic Group Meeting on October 27th - 29th at le Royal Hotel.
